BCAN's Patient Handbook - Bladder Cancer Basics for the Newly Diagnosed



Donate Now to Support the Bladder Cancer Advocacy Network



Join The Online Bladder Cancer Support Community



The Bladder Cancer Advocacy Network (BCAN) is proud to announce that we have been designated a Marine Corps Marathon (MCM) Charity Partner! BCAN has been allocated 25 guaranteed entries for the 38th Annual Marine Corps Marathon to be held on October 27, 2013; an event that sold out in 2 hours and 41 minutes in 2012.
  • We are looking at building “Team BCAN” to not only run in the event and raise awareness for bladder cancer but to raise needed funds for fostering research and patient education. According to the Marine Corps Marathon, there is not a required qualifying time to participate in the event, but all runners should maintain at least a 14 minute mile pace. In order to become a member of “Team BCAN” and officially have a slot in this year’s race, you must be registered through BCAN.
  • No federal or Marine Corps endorsement is implied.
  • If you are interested in becoming a member of BCAN’s team or have any questions, please contact Larry Rzepka, BCAN’s Executive Director, at lrzepka@bcan.org.
  • abstadler.jpg
    Walter Stadler, M.D., FACP
    Associate Professor
    Department of Medicine, Section Hematology/Oncology
    Department of Surgery, Section of Urology
    University of Chicago
    Dr. Stadler received his undergraduate degree from the University of Illinois and his M.D. from Yale University School of Medicine. He received postgraduate training at Michael Reese Hospital and Medical Center as well as the University of Chicago.  He serves as director of the Genitourinary Oncology Program that focuses on novel therapeutic approaches to genitourinary malignancies as well as clinical applications of molecular prognostic and predictive markers for these diseases.  He also serves as chair of the Clinical Trials Review Committee for the University of Chicago Cancer Research Center and is cadre leader for renal cell cancer efforts in the Genitourinary Committee of the Cancer and Leukemia Group B (CALGB).  He has over 80 peer-reviewed publications, and is the principal investigator on a variety of bladder, kidney, and prostate investigative protocols.  He is an active member of a number of cancer and urology related societies including American Society of Clinical Oncology, American Urology Association, American Association for Cancer Research, Society of Urologic Oncology, and Society for Basic Urologic Research.  His work has been supported by various agencies and societies including the American Cancer Society, and the National Institute of Health.
    Click here for more information.